Abstract:Chimeric antigen receptor (CAR) T-cell therapy entails the genetic engineering of a patient's T-cells to express membrane spanning fusion receptors with defined specificities for tumor-associated antigens. These CARs are capable of eliciting robust T-cell activation to initiate killing of the target tumor cells. This therapeutic approach has produced unprecedented clinical outcomes in the treatment of "liquid" hematologic cancers, but to date has not produced comparable responses in targeting solid malignancies. Advances in our understanding of the immunobiology of solid tumors have highlighted several hurdles which currently hinder the efficacy of this therapy. These barriers include the insufficient accumulation of CAR T-cells in the tumor due to poor trafficking or physical exclusion and the exposure of infiltrating CAR T-cells to a panoply of immune suppressive checkpoint molecules, cytokines, and metabolic stresses that are not conducive to efficient immune reactions and can thereby render these cells anergic, exhausted, or apoptotic. This mini-review summarizes these hurdles and describes some recent approaches and innovations to genetically re-engineer CAR T-cells to counter inhibitory influences found in the tumor microenvironment. Novel immunotherapy drug combinations to potentiate the activity of CAR T-cells are also discussed. As our understanding of the immune landscape of tumors improves and our repertoire of immunotherapeutic drugs expands, it is envisaged that the efficacy of CAR T-cells against solid tumors might be potentiated using combination therapies, which it is hoped may lead to meaningful improvements in clinical outcome for patients with refractory solid malignancies.

CAR-T Therapies in Solid Tumors: Opportunities and Challenges

Prospects and challenges for use of CAR T cell therapies in solid tumors

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Chimeric Antigen Receptor T Cells Applied to Solid Tumors

Challenges and strategies in relation to effective CAR-T cell immunotherapy for solid tumors

Current Progress in CAR-T Cell Therapy for Solid Tumors

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors

Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy

CAR-T cell therapy: current limitations and potential strategies

Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

A long way to the battlefront: CAR T cell therapy against solid cancers.

CAR-T cells and BiTEs in solid tumors: challenges and perspectives

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

Hurdles of CAR-T Cell-Based Cancer Immunotherapy Directed Against Solid Tumors.

CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments